{"id":34675,"date":"2026-03-10T17:55:00","date_gmt":"2026-03-10T12:25:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=34675"},"modified":"2026-03-11T10:19:18","modified_gmt":"2026-03-11T04:49:18","slug":"pharma-news-for-roche-ipsen-bms","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-ipsen-bms","title":{"rendered":"Roche Reveals Update from Phase III persevERA Study Targeting ER-Positive Advanced Breast Cancer; Ipsen Confirms Voluntary Withdrawal of TAZVERIK for Select Oncology Indications; Bristol Myers Squibb Unveils Positive Phase 3 Data from SUCCESSOR-2 Study Evaluating Mezigdomide in R\/R Multiple Myeloma; Servier Announces Acquisition of Day One Biopharmaceuticals to Bolster Rare Cancer Portfolio; Pfizer Advances Trispecific Antibody with Positive Phase 2 Results in Atopic Dermatitis"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69ef841c30fa9\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69ef841c30fa9\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-ipsen-bms\/#Roche_Announces_Latest_Findings_from_Phase_III_persevERA_Study_in_ER-Positive_Advanced_Breast_Cancer\" >Roche Announces Latest Findings from Phase III persevERA Study in ER-Positive Advanced Breast Cancer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-ipsen-bms\/#Ipsen_Withdraws_TAZVERIK_tazemetostat_for_Follicular_Lymphoma_and_Epithelioid_Sarcoma\" >Ipsen Withdraws TAZVERIK (tazemetostat) for Follicular Lymphoma and Epithelioid Sarcoma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-ipsen-bms\/#Bristol_Myers_Squibb_Shares_Encouraging_Phase_3_SUCCESSOR-2_Results_for_Mezigdomide_in_RR_Multiple_Myeloma\" >Bristol Myers Squibb Shares Encouraging Phase 3 SUCCESSOR-2 Results for Mezigdomide in R\/R Multiple Myeloma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-ipsen-bms\/#Servier_to_Acquire_Day_One_Biopharmaceuticals_to_Strengthen_Rare_Oncology_Portfolio\" >Servier to Acquire Day One Biopharmaceuticals to Strengthen Rare Oncology Portfolio<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-ipsen-bms\/#Pfizer_Reports_Positive_Phase_2_Results_for_Trispecific_Antibody_in_Moderate-to-Severe_Atopic_Dermatitis\" >Pfizer Reports Positive Phase 2 Results for Trispecific Antibody in Moderate-to-Severe Atopic Dermatitis<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-roche-announces-latest-findings-from-phase-iii-persevera-study-in-er-positive-advanced-breast-cancer\"><span class=\"ez-toc-section\" id=\"Roche_Announces_Latest_Findings_from_Phase_III_persevERA_Study_in_ER-Positive_Advanced_Breast_Cancer\"><\/span>Roche Announces Latest Findings from Phase III persevERA Study in ER-Positive Advanced Breast Cancer<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Roche <\/strong>announced results from the <strong>Phase III persevERA Breast Cancer study<\/strong> evaluating the investigational oral <a href=\"https:\/\/www.delveinsight.com\/report-store\/serd-market-forecast\">selective estrogen receptor degrader (SERD)<\/a> <strong>giredestrant<\/strong> in combination with the CDK4\/6 inhibitor <strong>palbociclib<\/strong> for patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer.<\/p>\n\n\n\n<p>The study assessed whether the combination therapy could improve outcomes compared with standard endocrine therapy combined with a <a href=\"https:\/\/www.delveinsight.com\/report-store\/cdk4-6-inhibitor-market-forecast\">CDK4\/6 inhibitor<\/a> in patients whose disease had progressed following prior treatment. Results demonstrated that the <strong>giredestrant-based regimen significantly improved progression-free survival (PFS)<\/strong>, meaning it delayed the worsening or progression of the disease compared with the standard-of-care comparator arm.<\/p>\n\n\n\n<p>Giredestrant is designed to degrade the estrogen receptor, which plays a critical role in the growth of many breast cancers. Unlike some existing treatments, it is administered orally and aims to overcome resistance mechanisms that often develop with endocrine therapy. According to Roche, these findings reinforce the potential of giredestrant as an important next-generation endocrine therapy for hormone-receptor\u2013positive breast cancer.<\/p>\n\n\n\n<p>The persevERA trial is part of Roche\u2019s broader clinical development program evaluating giredestrant across different treatment settings, including early-stage disease and first-line advanced disease. Previous studies, such as evERA and lidERA have also shown promising results supporting its potential role across the breast-cancer treatment continuum.<\/p>\n\n\n\n<p>Investigators noted that resistance to endocrine therapies remains a major challenge in ER-positive breast cancer, particularly after exposure to CDK4\/6 inhibitors. The giredestrant combination approach may provide an additional treatment option aimed at delaying disease progression and improving patient outcomes.<\/p>\n\n\n\n<p>Roche plans to present the detailed data at upcoming scientific meetings and discuss the results with health authorities. If supported by further evidence and regulatory review, giredestrant could potentially become a new treatment standard for patients with advanced hormone-receptor\u2013positive breast cancer who have limited options after disease progression.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ipsen-withdraws-tazverik-tazemetostat-for-follicular-lymphoma-and-epithelioid-sarcoma\"><span class=\"ez-toc-section\" id=\"Ipsen_Withdraws_TAZVERIK_tazemetostat_for_Follicular_Lymphoma_and_Epithelioid_Sarcoma\"><\/span>Ipsen Withdraws TAZVERIK (tazemetostat) for Follicular Lymphoma and Epithelioid Sarcoma<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Ipsen <\/strong>announced that it will <strong>voluntarily withdraw the cancer medicine TAZVERIK (tazemetostat)<\/strong> from the market for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/follicular-lymphoma-market-insights\">treatment of follicular lymphoma<\/a> and epithelioid sarcoma. The decision follows emerging safety data from the ongoing <strong>Phase Ib\/III SYMPHONY-1 clinical trial<\/strong>.<\/p>\n\n\n\n<p>TAZVERIK is an inhibitor of the EZH2 methyltransferase enzyme and has previously been approved for certain patients with follicular lymphoma and epithelioid sarcoma. However, the Independent Data Monitoring Committee (IDMC) overseeing the <strong>SYMPHONY-1 study<\/strong> identified cases of secondary hematologic malignancies in patients receiving treatment regimens that included tazemetostat. Based on this emerging safety signal, the committee concluded that the potential risks may outweigh the expected clinical benefits for patients in this setting.<\/p>\n\n\n\n<p>Following the recommendation of the IDMC, Ipsen decided to withdraw TAZVERIK in all indications across its markets, effective immediately. The company stated that patient safety remains its highest priority and that the withdrawal reflects a precautionary measure in response to the safety findings.<\/p>\n\n\n\n<p>Ipsen is working with health authorities and healthcare professionals to ensure an orderly discontinuation of the therapy and to provide guidance for physicians treating patients currently receiving TAZVERIK. Physicians are advised to discuss alternative treatment options with affected patients and manage therapy transitions appropriately.<\/p>\n\n\n\n<p>The SYMPHONY-1 trial had been evaluating tazemetostat in combination with lenalidomide and rituximab compared with the lenalidomide-rituximab regimen alone in patients with follicular lymphoma. The trial\u2019s safety findings prompted the reassessment of the drug\u2019s overall benefit-risk profile.<\/p>\n\n\n\n<p>Ipsen noted that it remains committed to advancing its oncology pipeline and continues to invest in innovative treatments for cancers with high unmet medical need. The withdrawal of TAZVERIK underscores the importance of ongoing clinical monitoring to ensure that approved medicines maintain a favorable safety profile for patients.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-bristol-myers-squibb-shares-encouraging-phase-3-successor-2-results-for-mezigdomide-in-r-r-multiple-myeloma\"><span class=\"ez-toc-section\" id=\"Bristol_Myers_Squibb_Shares_Encouraging_Phase_3_SUCCESSOR-2_Results_for_Mezigdomide_in_RR_Multiple_Myeloma\"><\/span>Bristol Myers Squibb Shares Encouraging Phase 3 SUCCESSOR-2 Results for Mezigdomide in R\/R Multiple Myeloma<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Bristol Myers Squibb<\/strong> announced positive interim Phase III results from the<strong> SUCCESSOR-2 clinical trial<\/strong>, evaluating <strong>mezigdomide<\/strong> combined with <strong>carfilzomib and dexamethasone<\/strong> in patients with <a href=\"https:\/\/www.delveinsight.com\/report-store\/relapsed-refractory-multiple-myeloma-market\">relapsed or refractory multiple myeloma (RRMM)<\/a>.<\/p>\n\n\n\n<p>The study demonstrated that the regimen containing mezigdomide achieved a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with the control regimen of carfilzomib plus dexamethasone alone. Progression-free survival measures the time during and after treatment in which the disease does not worsen.<\/p>\n\n\n\n<p>Mezigdomide is part of the company\u2019s <strong>CELMoD platform<\/strong>, a next-generation class of immunomodulatory drugs designed to enhance immune-mediated destruction of cancer cells while improving potency compared with earlier IMiD therapies. The compound works through targeted protein degradation mechanisms that promote the elimination of proteins involved in tumor growth.<\/p>\n\n\n\n<p>Patients enrolled in SUCCESSOR-2 had multiple myeloma that had relapsed or no longer responded to previous therapies, including anti-CD38 antibodies and lenalidomide. These patients often have limited treatment options, highlighting the importance of new therapeutic strategies.<\/p>\n\n\n\n<p>Safety findings from the trial were consistent with the known safety profile of mezigdomide and the drug combination. Patients in the study will continue to be followed for overall survival, long-term safety, and other clinical endpoints.<\/p>\n\n\n\n<p>Bristol Myers Squibb plans to present the full data from the trial at an upcoming medical conference and intends to discuss the results with regulatory authorities. The positive findings strengthen confidence in the company\u2019s CELMoD platform and support the continued development of mezigdomide as a potential new treatment option for patients with difficult-to-treat multiple myeloma.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-servier-to-acquire-day-one-biopharmaceuticals-to-strengthen-rare-oncology-portfolio\"><span class=\"ez-toc-section\" id=\"Servier_to_Acquire_Day_One_Biopharmaceuticals_to_Strengthen_Rare_Oncology_Portfolio\"><\/span>Servier to Acquire Day One Biopharmaceuticals to Strengthen Rare Oncology Portfolio<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Servier <\/strong>announced that it has entered into a definitive agreement to acquire <strong>Day One Biopharmaceuticals for approximately $2.5 billion<\/strong>. The acquisition is intended to strengthen Servier\u2019s presence in rare oncology, particularly in pediatric cancers.<\/p>\n\n\n\n<p>Under the terms of the agreement, Servier will acquire all outstanding shares of Day One for <strong>$21.50 per share in cash<\/strong>, representing a significant premium compared with the company\u2019s recent trading price. The transaction will be executed through a tender offer followed by a merger once the required number of shares has been acquired.<\/p>\n\n\n\n<p>Day One Biopharmaceuticals focuses on developing targeted therapies for life-threatening diseases affecting both children and adults. Its pipeline includes treatments designed for <a href=\"https:\/\/www.delveinsight.com\/report-store\/low-grade-glioma-market\">pediatric low-grade glioma<\/a>, a rare childhood brain tumor with limited treatment options. By acquiring Day One, Servier aims to enhance its portfolio of innovative oncology therapies and expand its pipeline across multiple stages of development.<\/p>\n\n\n\n<p>The deal aligns with Servier\u2019s long-term strategy and 2030 ambition to advance innovative treatments for cancers with high unmet medical needs. The combined expertise of Servier and Day One is expected to accelerate research and development and broaden global access to novel cancer therapies.<\/p>\n\n\n\n<p>The servier intends to fund the acquisition using existing cash and investments. The transaction is subject to customary closing conditions, including regulatory approvals and acceptance of the tender offer by a majority of Day One shareholders. The companies expect the acquisition to close in the second quarter of 2026.<\/p>\n\n\n\n<p>Following completion, Day One\u2019s scientific capabilities and pipeline will be integrated into Servier\u2019s global oncology operations, reinforcing its commitment to developing targeted therapies for rare cancers.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pfizer-reports-positive-phase-2-results-for-trispecific-antibody-in-moderate-to-severe-atopic-dermatitis\"><span class=\"ez-toc-section\" id=\"Pfizer_Reports_Positive_Phase_2_Results_for_Trispecific_Antibody_in_Moderate-to-Severe_Atopic_Dermatitis\"><\/span>Pfizer Reports Positive Phase 2 Results for Trispecific Antibody in Moderate-to-Severe Atopic Dermatitis<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Pfizer <\/strong>reported positive topline results from a Phase II clinical trial evaluating the investigational trispecific antibody <strong>tilrekimig (PF-07275315)<\/strong> in adults with <a href=\"https:\/\/www.delveinsight.com\/report-store\/moderate-to-severe-atopic-dermatitis-market\">moderate-to-severe atopic dermatitis<\/a>, a chronic inflammatory skin disease.<\/p>\n\n\n\n<p>The trial met its primary endpoint, demonstrating a statistically significant increase in the proportion of patients achieving EASI-75, defined as at least a 75% reduction in the Eczema Area and Severity Index at Week 16 compared with placebo. Across tested doses, placebo-adjusted response rates ranged from approximately 38.7% to 51.9%, indicating meaningful clinical improvements in disease severity.<\/p>\n\n\n\n<p>Tilrekimig is designed as a trispecific antibody targeting three inflammatory pathways simultaneously, interleukin-4 (IL-4), <a href=\"https:\/\/www.delveinsight.com\/report-store\/interleukin-13-inhibitors-market\">interleukin-13 (IL-13)<\/a>, and thymic stromal lymphopoietin (TSLP). These pathways play key roles in Type-2 immune responses that drive conditions such as atopic dermatitis, asthma, and chronic obstructive pulmonary disease (COPD). By blocking all three pathways with a single therapy, tilrekimig aims to provide broader and more durable control of inflammation.<\/p>\n\n\n\n<p>The drug demonstrated a favorable safety and tolerability profile during the trial. The study also evaluated different monthly dosing regimens, and results suggested that a once-monthly administration could deliver competitive efficacy relative to existing biologic therapies.<\/p>\n\n\n\n<p>Based on these encouraging findings, Pfizer plans to advance tilrekimig into Phase III development, with a pivotal trial in atopic dermatitis expected to begin later in 2026. If successful, the therapy could become a first-in-class trispecific antibody for treating chronic inflammatory diseases.<\/p>\n\n\n\n<p>The results strengthen Pfizer\u2019s inflammation and immunology pipeline and highlight the growing role of multi-target antibody therapies in addressing complex immune-mediated diseases.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Roche Announces Latest Findings from Phase III persevERA Study in ER-Positive Advanced Breast Cancer Roche announced results from the Phase III persevERA Breast Cancer study evaluating the investigational oral selective estrogen receptor degrader (SERD) giredestrant in combination with the CDK4\/6 inhibitor palbociclib for patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer. The study [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":34678,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[7478,127,18834,20494,410],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-34675","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-atopic-dermatitis","tag-breast-cancer","tag-follicular-lymphoma","tag-low-grade-glioma","tag-multiple-myeloma","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Roche, Ipsen, Bristol Myers Squibb<\/title>\n<meta name=\"description\" content=\"Roche\u2019s giredestrant; Ipsen\u2019s TAZVERIK; Bristol Myers Squibb\u2019s Mezigdomide; Servier\u2019s Day One Biopharmaceuticals Acquisition\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-ipsen-bms\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Roche, Ipsen, Bristol Myers Squibb\" \/>\n<meta property=\"og:description\" content=\"Roche\u2019s giredestrant; Ipsen\u2019s TAZVERIK; Bristol Myers Squibb\u2019s Mezigdomide; Servier\u2019s Day One Biopharmaceuticals Acquisition\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-ipsen-bms\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-10T12:25:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-11T04:49:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/pharma-news-assessment-for-roche-ipsen-bms.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Roche, Ipsen, Bristol Myers Squibb","description":"Roche\u2019s giredestrant; Ipsen\u2019s TAZVERIK; Bristol Myers Squibb\u2019s Mezigdomide; Servier\u2019s Day One Biopharmaceuticals Acquisition","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-ipsen-bms","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Roche, Ipsen, Bristol Myers Squibb","og_description":"Roche\u2019s giredestrant; Ipsen\u2019s TAZVERIK; Bristol Myers Squibb\u2019s Mezigdomide; Servier\u2019s Day One Biopharmaceuticals Acquisition","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-ipsen-bms","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2026-03-10T12:25:00+00:00","article_modified_time":"2026-03-11T04:49:18+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/pharma-news-assessment-for-roche-ipsen-bms.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-ipsen-bms","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-ipsen-bms","name":"Pharma News | Roche, Ipsen, Bristol Myers Squibb","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-ipsen-bms#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-ipsen-bms#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/pharma-news-assessment-for-roche-ipsen-bms.webp","datePublished":"2026-03-10T12:25:00+00:00","dateModified":"2026-03-11T04:49:18+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Roche\u2019s giredestrant; Ipsen\u2019s TAZVERIK; Bristol Myers Squibb\u2019s Mezigdomide; Servier\u2019s Day One Biopharmaceuticals Acquisition","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-ipsen-bms"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-roche-ipsen-bms#primaryimage","url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/pharma-news-assessment-for-roche-ipsen-bms.webp","contentUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/pharma-news-assessment-for-roche-ipsen-bms.webp","width":772,"height":482,"caption":"pharma-news-assessment-for-roche-ipsen-bms"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/03\/pharma-news-assessment-for-roche-ipsen-bms-300x187.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Atopic dermatitis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Breast Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Follicular Lymphoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Low-Grade Glioma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Multiple Myeloma<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Atopic dermatitis<\/span>","<span class=\"advgb-post-tax-term\">Breast Cancer<\/span>","<span class=\"advgb-post-tax-term\">Follicular Lymphoma<\/span>","<span class=\"advgb-post-tax-term\">Low-Grade Glioma<\/span>","<span class=\"advgb-post-tax-term\">Multiple Myeloma<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 months ago","modified":"Updated 2 months ago"},"absolute_dates":{"created":"Posted on Mar 10, 2026","modified":"Updated on Mar 11, 2026"},"absolute_dates_time":{"created":"Posted on Mar 10, 2026 5:55 pm","modified":"Updated on Mar 11, 2026 10:19 am"},"featured_img_caption":"pharma-news-assessment-for-roche-ipsen-bms","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/34675","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=34675"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/34675\/revisions"}],"predecessor-version":[{"id":34676,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/34675\/revisions\/34676"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/34678"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=34675"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=34675"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=34675"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=34675"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=34675"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}